OTSKF - Cullinan reports zipalertinib study met primary endpoint
2025-01-29 12:17:55 ET
More on Cullinan Therapeutics
- Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
- Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
- Seeking Alpha’s Quant Rating on Cullinan Therapeutics
- Historical earnings data for Cullinan Therapeutics
- Financial information for Cullinan Therapeutics